Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polymorphisms of metabolic enzymes and transporters and PK/response to imatinib, dasatinib and nilotinib
ChiCTR-RPC-16010078Phase 4Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Dec 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of imatinib, dasatinib and nilotinib in chronic myelogenous leukemia (CML) (3 arms), sponsored by The Second Xiangya Hospital. Primary endpoints: Plasma concentrations of imatinib, dasatinib or nilotinib and Genotype of metabolic enzymes and transporters. Started Dec 2016; status: recruiting.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ChiCTR-RPC-16010078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-RPC-16010078.